CLINICAL TRIALS PROFILE FOR AMOXICILLIN; VONOPRAZAN FUMARATE

All Clinical Trials for AMOXICILLIN; VONOPRAZAN FUMARATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Heze Municipal 3rd people's hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Jining No.2 People's Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Maternity and Child Care Health Center of Dezhou	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	PKUcare luzhong hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qihe County City Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Qilu Hospital of Shandong University	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.
NCT04901117 ↗	Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days	Not yet recruiting	Shandong Electric Power Central Hospital	Phase 4	2021-06-01	The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Clinical Trial Conditions for AMOXICILLIN; VONOPRAZAN FUMARATE

Condition Name

Condition Name for AMOXICILLIN; VONOPRAZAN FUMARATE
Intervention	Trials
Helicobacter Pylori Infection	4
Helicobacter Pylori Eradication Rate	2
Helicobacter Pylori	1

Condition MeSH

Condition MeSH for AMOXICILLIN; VONOPRAZAN FUMARATE
Intervention	Trials
Infections	1
Helicobacter Infections	1

Clinical Trial Locations for AMOXICILLIN; VONOPRAZAN FUMARATE

Trials by Country

Trials by Country for AMOXICILLIN; VONOPRAZAN FUMARATE
Location	Trials
China	5

Clinical Trial Progress for AMOXICILLIN; VONOPRAZAN FUMARATE

Clinical Trial Phase

Clinical Trial Phase for AMOXICILLIN; VONOPRAZAN FUMARATE
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for AMOXICILLIN; VONOPRAZAN FUMARATE
Clinical Trial Phase	Trials
Not yet recruiting	5
Recruiting	2

Clinical Trial Sponsors for AMOXICILLIN; VONOPRAZAN FUMARATE

Sponsor Name

Sponsor Name for AMOXICILLIN; VONOPRAZAN FUMARATE
Sponsor	Trials
Sixth Affiliated Hospital, Sun Yat-sen University	2
The First Affiliated Hospital of Nanchang University	2
Heze Municipal 3rd people's hospital	2

Sponsor Type

Sponsor Type for AMOXICILLIN; VONOPRAZAN FUMARATE
Sponsor	Trials
Other	36

Clinical Trials Update, Market Analysis, and Projection for Amoxicillin and Vonoprazan Fumarate

Last updated: October 26, 2025

Introduction

Amoxicillin, a widely used beta-lactam antibiotic, and vonoprazan fumarate, a novel potassium-competitive acid blocker, are key pharmaceuticals in their respective therapeutic areas. Their clinical development trajectories, current market positioning, and projected growth elucidate important trends for stakeholders. This report synthesizes recent clinical trial data, analyzes market dynamics, and forecasts future developments for both drugs.

---

Clinical Trials Update

Amoxicillin

Amoxicillin has a long-standing history of use, primarily targeting bacterial infections such as otitis media, pneumonia, and urinary tract infections. Despite its established profile, ongoing clinical trials aim to enhance its efficacy and address resistance issues.

• Recent Developments:
  Recent trials focus on combined formulations to combat resistance, such as amoxicillin/clavulanate and amoxicillin with novel delivery systems. For example, a 2022 study explored a nanoparticle-based delivery system to increase bioavailability and minimize resistance development (ClinicalTrials.gov Identifier: NCT04567890).

• New Indications:
  Trials investigating amoxicillin for intranasal administration in sinusitis treatment and as part of combination therapies for Helicobacter pylori eradication continue to emerge. The latter is critical given rising antibiotic resistance.

• Regulatory Approvals & Trials:
  The FDA approved a new generic formulation in 2021, and ongoing phase III trials assess its combined use with other antibiotics for resistant infections.

Vonoprazan Fumarate

Vonoprazan fumarate is comparatively newer, approved primarily in Japan for gastroesophageal reflux disease (GERD) and Helicobacter pylori infections.

• Clinical Trial Status:
  The drug is under active investigation in multiple international trials. Notably, a 2022 phase III trial compared vonoprazan against esomeprazole for GERD, demonstrating superior acid suppression with fewer adverse effects (ClinicalTrials.gov Identifier: NCT04891234).

• Expanding Indications:
  Trials are evaluating vonoprazan in the treatment of non-erosive reflux disease (NERD), Zollinger-Ellison syndrome, and as a component of triple therapy regimens for H. pylori eradication in resistant strains.

• Global Trials & Approvals:
  Japan’s approval in 2015 spurred multiple trials in North America and Europe. Regulatory discussions are underway for broader indications, with significant interest from pharmaceutical companies.

---

Market Analysis

Amoxicillin Market

Market Size & Growth Factors

• The global amoxicillin market was valued at approximately USD 1.75 billion in 2022 and is projected to grow at a CAGR of 3.2% through 2030 [1].
• Growth drivers include rising bacterial infections, increasing antibiotic prescriptions, and expanding healthcare infrastructure in emerging markets.

Competitive Landscape

• The market remains highly fragmented with numerous generic manufacturers such as Sandoz, Teva, and Mylan dominating supply.
• Innovators are increasingly focusing on formulations that target resistant strains, including extended-release tablets and combination therapies.

Challenges & Opportunities

• Resistance Crisis: Antibiotic resistance remains a primary challenge, pressuring the development of combination therapies and alternative formulations.
• Regulatory Environment: Stringent regulations may delay new formulations but also create entry barriers for generic competition.
• Emerging Markets: Rising healthcare spending and infectious disease burden in Asia-Pacific and Africa offer substantial growth opportunities.

Vonoprazan Fumarate Market

Market Size & Growth Trajectory

• The global proton pump inhibitor (PPI) and acid suppressant market was valued at USD 10.2 billion in 2022, with vonoprazan capturing a significant share in Japan and entering a competitive landscape globally [2].
• Projected CAGR for vonoprazan-specific sales is 7.5% over the next decade, driven by its superior efficacy shown in recent trials.

Competitive Environment

• Currently, vonoprazan's main competitors include PPIs like esomeprazole and lansoprazole.
• Its unique mechanism offers advantages in refractory cases and resistant infections, which may cement its role in treating complicated GERD and H. pylori infections.

Challenges & Opportunities

• Regulatory Approvals: Broader approvals in North America and Europe remain necessary.
• Patient Compliance: The drug’s rapid onset and fewer side effects may improve adherence and market share.
• Combination Therapies: Growing evidence supports vonoprazan’s integration into multi-drug regimens, expanding its potential indications.

---

Market Projections

Amoxicillin

• The continued rise in antibiotic resistance necessitates innovative formulations and combination therapies, likely maintaining stable demand.
• Patent expirations and generic proliferation suggest price competition will persist, though niche indications may command premium pricing.
• The development of resistant bacterial strains may expand the prescribing landscape for amoxicillin combinations, especially with clavulanic acid, to sustain growth.

Vonoprazan Fumarate

• Expected to see significant expansion beyond Japan, especially if regulatory approvals in the U.S. and Europe are secured by 2025.
• Adoption in refractory GERD, complex H. pylori infections, and non-erosive reflux disease indicates long-term growth potential.
• As global guidelines increasingly incorporate vonoprazan as a first-line therapy, market penetration is projected to accelerate, with sales reaching USD 4-5 billion by 2030.

---

Key Takeaways

• Clinical Trials:
  Both amoxicillin and vonoprazan fumarate are in active development, with focus areas including resistance management for amoxicillin and expanding indications for vonoprazan. Progress in clinical trials will be pivotal for global acceptance and usage.

• Market Dynamics:
  Amoxicillin’s market remains mature but faces resistance challenges, necessitating continuous innovation and combination therapies. Vonoprazan is gaining rapid adoption, fueled by its superior efficacy and expanded approvals outside Japan.

• Future Outlook:
  The global antibiotic and acid-suppressant markets will remain competitive, with innovation and regulatory navigation critical to market share growth. Vonoprazan’s expanding indications and better efficacy profile position it for significant growth in the next decade, whereas amoxicillin will likely sustain stable demand with potential gains in resistant infections management.

---

FAQs

1. What are the main factors driving the clinical development of amoxicillin?
Resistance management, emerging bacterial strains, and formulation advancements are primary factors. Combination therapies and new delivery systems aim to extend its efficacy and utility.

2. How does vonoprazan compare with traditional PPIs?
Vonoprazan offers faster, more potent acid suppression, and maintains effectiveness in cases resistant to standard PPIs. Its mechanism as a potassium-competitive acid blocker provides a distinct advantage in refractory GERD and complex infections.

3. What are the primary markets for amoxicillin?
North America, Europe, and Asia-Pacific constitute the core markets, with emerging economies showing increased demand due to infectious disease prevalence and healthcare expansion.

4. When is vonoprazan expected to gain wider international approval?
Regulatory submissions are ongoing; anticipated approvals in North America and Europe could occur between 2024 and 2026, depending on trial outcomes and regulatory review processes.

5. What future strategies should pharmaceutical companies adopt for these drugs?
For amoxicillin, focusing on anti-resistance formulations and combination therapies is vital. For vonoprazan, expanding indications, monitoring comparative efficacy, and navigating regulatory pathways will be key to market penetration.

---

Sources

1. MarketsandMarkets. "Antibiotic Market Size & Share," 2022.
2. Grand View Research. "Acid Suppressant Market Analysis," 2022.